It has been shown that T cells engineered to express CXCR2 will preferentially traffic to melanomas 102, whereas T cells expressing CCR4 will traffic to Hodgkin's lymphoma 2009. The gene discussed is CCR4; the disease is Hodgkins lymphoma.